Author Topic: (ECTRIMS) MS therapy GNbAC1 promotes myelin rejuvenation, study shows  (Read 65 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8520
  • MS diagnosed 1980
  • Location: Pacific Northwest
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8520
  • MS diagnosed 1980
  • Location: Pacific Northwest
Update on temelimab (GNbAC1)
« Reply #1 on: April 27, 2020, 08:52:50 pm »
Trials of GNbAC1 (temelimab) have been delayed due to the COVID-19 outbreak. Some information about it:


https://www.mstrust.org.uk/a-z/temelimab


About the postponement, from  Yahoo Finance News (April 26, 2020):


https://finance.yahoo.com/news/geneuro-financial-information-business-first-053000714.html



MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
93 Views
Last post September 04, 2017, 09:29:59 pm
by agate
0 Replies
46 Views
Last post November 20, 2017, 03:48:24 pm
by agate
0 Replies
32 Views
Last post May 09, 2018, 04:42:45 pm
by agate
0 Replies
22 Views
Last post April 19, 2019, 02:37:42 pm
by agate
0 Replies
25 Views
Last post September 14, 2019, 06:56:51 pm
by agate